Trial Profile

A Phase II Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DFP 13318 (Primary)
Indications Advanced breast cancer; Carcinoma; Male breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms TOPOLOGY

Most Recent Events

04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
16 May 2024 Planned End Date changed from 15 Feb 2026 to 19 Mar 2026.
16 May 2024 Planned primary completion date changed from 15 Jul 2025 to 19 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com